You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 30, 2025

CLINICAL TRIALS PROFILE FOR GOLYTELY


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Golytely

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00380497 ↗ Pico-Salax Versus Poly-Ethylene Glycol for Bowel Cleanout Before Colonoscopy in Children Completed The Hospital for Sick Children Phase 4 2006-09-01 The purpose of this trial is to compare patient's satisfaction from Pico-Salax with the standard of care, Poly-Ethylene Glycol and electrolyte solution, for bowel cleanout before colonoscopy in children, and to compare effectiveness.
NCT00611442 ↗ Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus Placebo in Outpatient Colonoscopy Completed Takeda N/A 2007-10-01 The primary outcomes of this procedure will be: 1. The cleanliness of the prep as measured by the Ottawa Scale (attachment a). Secondary outcomes will be: 1. Patient satisfaction with the prep measured by 5 point Likert scale (attachment b); 2. Procedure time; 3. The number and size of polyps detected on examination.
NCT00611442 ↗ Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus Placebo in Outpatient Colonoscopy Completed Brooke Army Medical Center N/A 2007-10-01 The primary outcomes of this procedure will be: 1. The cleanliness of the prep as measured by the Ottawa Scale (attachment a). Secondary outcomes will be: 1. Patient satisfaction with the prep measured by 5 point Likert scale (attachment b); 2. Procedure time; 3. The number and size of polyps detected on examination.
NCT00645801 ↗ Amitiza® Plus GoLYTELY® Versus Placebo Plus GoLYTELY® for Outpatient Colonoscopy Preparation Completed Takeda Pharmaceuticals North America, Inc. Phase 4 2008-03-01 The primary objective is to compare the effectiveness and tolerance of Amitiza® (lubiprostone) plus GoLYTELY® (polyethylene glycol-electrolyte solution) versus placebo and GoLYTELY ® (polyethylene glycol-electrolyte solution) as a bowel cleansing preparation for colonoscopy.
NCT00645801 ↗ Amitiza® Plus GoLYTELY® Versus Placebo Plus GoLYTELY® for Outpatient Colonoscopy Preparation Completed Henry Ford Health System Phase 4 2008-03-01 The primary objective is to compare the effectiveness and tolerance of Amitiza® (lubiprostone) plus GoLYTELY® (polyethylene glycol-electrolyte solution) versus placebo and GoLYTELY ® (polyethylene glycol-electrolyte solution) as a bowel cleansing preparation for colonoscopy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Golytely

Condition Name

Condition Name for Golytely
Intervention Trials
Colonoscopy 8
Bowel Preparation for Colonoscopy 2
Hepatic Encephalopathy 2
Cirrhosis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Golytely
Intervention Trials
Liver Cirrhosis 2
Hepatic Encephalopathy 2
Fibrosis 2
Brain Diseases 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Golytely

Trials by Country

Trials by Country for Golytely
Location Trials
United States 22
Canada 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Golytely
Location Trials
Texas 3
Connecticut 2
Pennsylvania 2
California 2
New York 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Golytely

Clinical Trial Phase

Clinical Trial Phase for Golytely
Clinical Trial Phase Trials
Phase 4 11
Phase 3 1
Phase 2 1
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Golytely
Clinical Trial Phase Trials
Completed 12
Not yet recruiting 3
Withdrawn 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Golytely

Sponsor Name

Sponsor Name for Golytely
Sponsor Trials
Mayo Clinic 2
Brooke Army Medical Center 2
VA Office of Research and Development 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Golytely
Sponsor Trials
Other 19
U.S. Fed 6
Industry 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

GOLYTELY: Clinical Trials, Market Analysis, and Projections

Introduction

GOLYTELY, a polyethylene glycol electrolyte solution, is a widely used bowel cleanser for preparations before colonoscopy and other gastrointestinal procedures. This article will delve into recent clinical trials, market analysis, and future projections for GOLYTELY.

Clinical Trials: Efficacy and Tolerability

Comparison with MiraLAX

A significant clinical trial compared the efficacy and tolerability of GOLYTELY with MiraLAX/Gatorade in patients undergoing screening colonoscopy. The study found that GOLYTELY was more efficacious in bowel cleansing than MiraLAX/Gatorade, with higher median total scores on the Boston Bowel Preparation Scale (BBPS). However, both preparations were equally tolerated by patients[1].

Comparison with MoviPrep

Another clinical trial compared GOLYTELY with MoviPrep, a low-volume bowel prep, to determine if MoviPrep is as effective but more tolerable for inpatients. This Phase 4 trial aimed to assess whether the lower volume of MoviPrep could reduce patient discomfort without compromising efficacy. While the trial is ongoing, previous studies have shown that GOLYTELY is a safe, effective, and well-tolerated method for bowel cleansing[4].

Clinical Trials: Methodology and Outcomes

Nasogastric Administration

For children with significant constipation, GOLYTELY can be administered via a nasogastric tube. This procedure, known as NG GOLYTELY cleanout, involves inserting a thin tube into the stomach to deliver the solution. The process is typically an all-day procedure and includes clear liquid diet, frequent walking, and toilet sitting to facilitate the cleanout. X-rays may be taken to confirm the success of the procedure[2].

Non-Inferiority Studies

A non-inferiority study aimed to determine if MiraLAX could be considered non-inferior to GOLYTELY in terms of prep quality scores. The study hypothesized that MiraLAX would have prep scores no more than 10% less than those of GOLYTELY. The results would help establish whether MiraLAX could be a viable alternative to GOLYTELY[3].

Market Analysis

Asia Pacific Market

The Asia Pacific Bowel Management Systems Market, which includes products like GOLYTELY, is expected to grow at a CAGR of 4.7% from 2019 to 2025. This growth is driven by the increasing need for effective bowel management systems, including irrigation systems and other products. The market is segmented by product, end use, patient category, and country, with key players such as Coloplast Group, 3M Company, and Medtronic PLC dominating the market[5].

Market Segmentation

The market for bowel management systems is segmented into several categories:

  • By Product: Irrigation systems, colostomy bags, nerve modulation devices, and other products.
  • By End Use: Home care, hospitals, and ambulatory surgery centers.
  • By Patient Category: Pediatric and adult.
  • By Country: China, Japan, India, South Korea, Singapore, Malaysia, and the rest of Asia Pacific[5].

Market Projections

Growth Drivers

The growth of the bowel management systems market, including GOLYTELY, is driven by several factors:

  • Increasing Prevalence of Gastrointestinal Disorders: The rising incidence of conditions requiring bowel cleansing and management is a significant driver.
  • Advancements in Technology: Improvements in irrigation systems and other bowel management products enhance efficacy and patient comfort.
  • Expanding Healthcare Infrastructure: Growing healthcare facilities and ambulatory surgery centers in the Asia Pacific region contribute to market growth[5].

Challenges and Opportunities

Despite the growth potential, the market faces challenges such as:

  • Patient Compliance: Ensuring patients adhere to the bowel prep regimen can be challenging.
  • Side Effects: Common side effects like nausea, vomiting, and abdominal pain may affect patient tolerance and compliance.
  • Cost and Accessibility: The cost of bowel management systems and accessibility in certain regions can be barriers to market growth.

However, opportunities exist in:

  • Innovative Products: Developing more tolerable and effective bowel prep solutions.
  • Expanding into New Markets: Entering emerging markets in the Asia Pacific region where healthcare infrastructure is improving[4][5].

Key Takeaways

  • Efficacy: GOLYTELY has been shown to be more efficacious than MiraLAX/Gatorade in bowel cleansing.
  • Tolerability: GOLYTELY and MiraLAX/Gatorade have similar tolerability profiles.
  • Market Growth: The Asia Pacific bowel management systems market is expected to grow at a CAGR of 4.7% from 2019 to 2025.
  • Segmentation: The market is segmented by product, end use, patient category, and country.
  • Growth Drivers: Increasing prevalence of gastrointestinal disorders, technological advancements, and expanding healthcare infrastructure drive market growth.

FAQs

What is GOLYTELY used for?

GOLYTELY is used as a bowel cleanser for preparations before colonoscopy, surgery, and other gastrointestinal procedures.

How is GOLYTELY administered?

GOLYTELY can be administered orally or via a nasogastric tube, especially in cases of significant constipation in children.

What are the common side effects of GOLYTELY?

Common side effects include nausea, vomiting, abdominal pain or cramps, bloating, and dehydration.

How does GOLYTELY compare to MiraLAX in terms of efficacy?

GOLYTELY has been shown to be more efficacious than MiraLAX/Gatorade in bowel cleansing, based on the Boston Bowel Preparation Scale (BBPS).

What is the projected market growth for bowel management systems including GOLYTELY?

The Asia Pacific bowel management systems market is expected to grow at a CAGR of 4.7% from 2019 to 2025.

Sources

  1. MiraLAX vs. Golytely - a controlled study of efficacy and patient tolerability. PubMed.
  2. NG GoLYTELY Cleanout. Children's Hospital of Philadelphia.
  3. Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy. Veeva Systems.
  4. MoviPrep vs GoLYTELY for Bowel Prep - Clinical Trials. WithPower.
  5. Asia Pacific Bowel Management Systems Market Size 2019-2025. KBV Research.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.